InvestorsHub Logo
Followers 42
Posts 5751
Boards Moderated 0
Alias Born 04/12/2021

Re: None

Friday, 09/23/2022 7:37:57 AM

Friday, September 23, 2022 7:37:57 AM

Post# of 119
“4:52a ET 9/23/2022 - Dow Jones
Spero Therapeutics Raised to Outperform From In-Line by Evercore ISI Group

Ratings actions from Benzinga: https://www.benzinga.com/stock/SPRO/ratings

(END) Dow Jones Newswires

September 23, 2022 04:52 ET (08:52 GMT)”

“4:42a ET 9/23/2022 - Benzinga
Evercore ISI Group Upgrades Spero Therapeutics to Outperform, Raises Price Target to $8

Evercore ISI Group analyst Josh Schimmer upgrades Spero Therapeutics (NASDAQ:SPRO) from In-Line to Outperform and raises the price target from $2 to $8.

Latest Ratings for SPRO DateFirmActionFromTo

Oct 2021OppenheimerDowngradesOutperformPerform Jan 2021HC Wainwright & Co.MaintainsBuy Dec 2020BerenbergInitiates Coverage OnBuy

View More Analyst Ratings for SPRO

View the Latest Analyst Ratings

© 2022 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.”

my posts are always theory and not financial advice

Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent SPRO News